MX2015006757A - Método para la evaluación de la presencia de o riesgo de tumores de colon. - Google Patents

Método para la evaluación de la presencia de o riesgo de tumores de colon.

Info

Publication number
MX2015006757A
MX2015006757A MX2015006757A MX2015006757A MX2015006757A MX 2015006757 A MX2015006757 A MX 2015006757A MX 2015006757 A MX2015006757 A MX 2015006757A MX 2015006757 A MX2015006757 A MX 2015006757A MX 2015006757 A MX2015006757 A MX 2015006757A
Authority
MX
Mexico
Prior art keywords
evaluation
risk
patient
response
colon tumors
Prior art date
Application number
MX2015006757A
Other languages
English (en)
Spanish (es)
Inventor
John Blume
Ryan Benz
Lisa Croner
Roslyn Dillon
Arlo Randall
Jeffrey Jones
Heather Skor
Tom Stockfisch
Bruce Wilcox
Daniel Ruderman
Original Assignee
Applied Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Proteomics Inc filed Critical Applied Proteomics Inc
Publication of MX2015006757A publication Critical patent/MX2015006757A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Bioethics (AREA)
MX2015006757A 2012-11-30 2013-12-02 Método para la evaluación de la presencia de o riesgo de tumores de colon. MX2015006757A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732024P 2012-11-30 2012-11-30
US201361772979P 2013-03-05 2013-03-05
PCT/US2013/072691 WO2014085826A2 (en) 2012-11-30 2013-12-02 Method for evaluation of presence of or risk of colon tumors

Publications (1)

Publication Number Publication Date
MX2015006757A true MX2015006757A (es) 2015-11-30

Family

ID=50828610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006757A MX2015006757A (es) 2012-11-30 2013-12-02 Método para la evaluación de la presencia de o riesgo de tumores de colon.

Country Status (11)

Country Link
US (6) US20140234854A1 (cg-RX-API-DMAC7.html)
EP (1) EP2926138A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016507723A (cg-RX-API-DMAC7.html)
KR (1) KR20150090240A (cg-RX-API-DMAC7.html)
CN (2) CN104969071B (cg-RX-API-DMAC7.html)
AU (1) AU2013351947A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012616A2 (cg-RX-API-DMAC7.html)
CA (1) CA2893158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015006757A (cg-RX-API-DMAC7.html)
SG (1) SG11201504241QA (cg-RX-API-DMAC7.html)
WO (1) WO2014085826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
CA2863819C (en) 2012-02-09 2021-11-23 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA2943827A1 (en) * 2014-03-28 2015-10-01 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
EP3167293B1 (en) * 2014-07-11 2020-03-18 Expression Pathology, Inc. Srm/mrm assay for the gtpase kras protein (kras)
EP3699930B1 (en) 2014-08-14 2024-02-07 MeMed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016037134A1 (en) * 2014-09-05 2016-03-10 Nantomics, Llc Systems and methods for determination of provenance
JP2017538938A (ja) * 2014-12-11 2017-12-28 ウイスコンシン・アルムニ・リサーチ・ファンデーション 大腸癌の検出及び処置方法
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
CN105807062A (zh) * 2014-12-28 2016-07-27 复旦大学 人结肠癌蛋白Spondin-2在制备结肠癌诊断制剂中的应用
CN105385752A (zh) * 2015-03-23 2016-03-09 复旦大学 一种人结肠癌蛋白质标志物Spondin-2的检测方法及其检测试剂盒
CA2982169A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP3316875B1 (en) * 2015-07-01 2021-11-17 Duke University Methods to diagnose acute respiratory infections
WO2017078787A1 (en) * 2015-11-05 2017-05-11 Vanderbilt University Protein quantitation in multicellular tissue specimens
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
EP3443497A1 (en) * 2016-04-11 2019-02-20 DiscernDx, Inc. Mass spectrometric data analysis workflow
JP6754116B2 (ja) * 2016-04-26 2020-09-09 学校法人近畿大学 大腸癌マーカー
CN107345236A (zh) * 2016-05-04 2017-11-14 北京美泽福临科技发展有限公司 一种amy2b信使rna的特异性扩增引物和肝癌辅助诊断试剂盒
CA3025004A1 (en) * 2016-06-10 2017-12-14 Wisconsin Alumni Research Foundation Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CN106202984B (zh) * 2016-08-26 2018-09-04 赵毅 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
EP3519834A4 (en) * 2016-09-29 2020-06-17 MeMed Diagnostics Ltd. RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS
US20180100858A1 (en) * 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CN110214271B (zh) * 2017-01-19 2022-11-15 株式会社岛津制作所 分析数据解析方法以及分析数据解析装置
US11204355B2 (en) 2017-02-20 2021-12-21 Vanderbilt University Immune checkpoint molecular fitness profiling by mass spectrometry
CN106919801B (zh) * 2017-03-08 2023-07-18 杭州大伽信息科技有限公司 一种免疫组织化学染色辅助分析系统及使用方法
CN106908608B (zh) * 2017-04-17 2018-10-02 首都医科大学附属北京胸科医院 辅助诊断重症继发性肺结核的蛋白标志物
US20180330059A1 (en) * 2017-05-09 2018-11-15 James Stewart Bates Patient treatment systems and methods
US10455457B2 (en) 2017-05-24 2019-10-22 Qualcomm Incorporated NR-SS unified operation mode in coordinated and uncoordinated bands
US11164679B2 (en) 2017-06-20 2021-11-02 Advinow, Inc. Systems and methods for intelligent patient interface exam station
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
CN111164700B (zh) * 2017-07-14 2024-10-29 余因子基因组学公司 使用下一代测序的免疫-肿瘤学应用
CN109406785A (zh) * 2017-08-18 2019-03-01 山东泽济生物科技有限公司 肿瘤血液标志物及其应用
EP3721232A1 (en) * 2017-12-05 2020-10-14 DiscernDx, Inc. Robust panels of colorectal cancer biomarkers
EP3732489B1 (en) * 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
ES2917629T3 (es) * 2018-01-22 2022-07-11 Liquid Biopsy Res Llc Métodos para la detección del cáncer de colon y monitorización del tratamiento
US11348688B2 (en) 2018-03-06 2022-05-31 Advinow, Inc. Systems and methods for audio medical instrument patient measurements
EP3776381A4 (en) 2018-04-13 2022-01-05 Freenome Holdings, Inc. IMPLEMENTATION OF MACHINE LEARNING FOR MULTI-ANALYTE TESTS OF BIOLOGICAL SAMPLES
EP3818376A1 (en) * 2018-07-05 2021-05-12 EDP Biotech Corporation Kits and methods for detecting markers
EA202190355A1 (ru) 2018-08-08 2021-05-25 Ридженерон Фармасьютикалз, Инк. Применение жх-мс/мс для количественного определения белковых биомаркеров
EP3623813A1 (en) * 2018-09-17 2020-03-18 Institut d'Investigació Sanitària Pere Virgili Methods for the prognosis of hiv-infected subjects
JP7539399B2 (ja) * 2019-03-06 2024-08-23 ディアデム エス．アール．エル． アルツハイマー病の診断と予後判定におけるマーカーとしてのｐ５３ペプチド
WO2021097302A1 (en) * 2019-11-13 2021-05-20 University Of South Florida Systems and methods of deep learning for colorectal polyp screening
CN110951707B (zh) * 2019-12-31 2022-11-11 南京医科大学 丙酮酸激酶m2突变体及其在心血管疾病中的应用
CN115616230A (zh) * 2020-03-18 2023-01-17 龙海市第一医院 用于肝癌早期诊断的检测岩藻糖基化载脂蛋白h的elisa试剂盒
WO2022006628A1 (en) * 2020-07-08 2022-01-13 Southern Adelaide Local Health Network Inc. Computer-implemented method and system for identifying measurable features for use in a predictive model
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
CN112034182A (zh) * 2020-09-01 2020-12-04 复旦大学附属中山医院 一种结肠癌转移预测方法和系统
CN112266961B (zh) * 2020-10-29 2023-05-12 中山大学附属第六医院 Tsg-6基因在预测结直肠癌转移及预后方面的应用
CN112710856B (zh) * 2020-12-16 2022-12-02 江西省肿瘤医院(江西省癌症中心) 检测血清igf1蛋白的制剂在制备结直肠癌疗效监测试剂中的应用
CN113447658B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
CN113956327B (zh) * 2021-10-11 2024-01-30 中山大学肿瘤防治中心 靶向人apc蛋白的多肽及其在制备药物中的应用
EP4497005A1 (en) * 2022-03-23 2025-01-29 Serum Detect, Inc. Biomarker signatures indicative of early stages of cancer
CN114445406B (zh) * 2022-04-07 2022-08-09 武汉大学 肠镜图像分析方法、装置和医学图像处理设备
TWI796228B (zh) 2022-05-25 2023-03-11 臺中榮民總醫院 急性腎損傷預測系統及其方法
CN114668836B (zh) * 2022-05-27 2022-08-19 暨南大学 Pdia6在制备治疗脊髓损伤和修复的药物中的应用
CN114958794B (zh) * 2022-06-14 2023-06-02 南京工业大学 一种苯乙醇胺-N-甲基转移酶hPNMT54及其克隆表达与应用
CN116593431B (zh) * 2023-04-09 2025-11-07 湖南科技大学三亚研究院 一种基于亲和传感器法的米酵菌酸毒素便携式检测装置及检测方法
WO2024232926A1 (en) * 2023-05-08 2024-11-14 Venn Biosciences Corporation Diagnosis of colorectal cancer using targeted quantification of peptides
WO2025058445A1 (ko) * 2023-09-15 2025-03-20 연세대학교 산학협력단 대장암에 대한 정보 제공 방법
CN118067993B (zh) * 2024-04-17 2024-07-05 弗雷米德生物医药技术（天津）有限公司 一种用于肠息肉检测的联检试剂盒及其制备方法、检测方法和应用
CN118496322A (zh) * 2024-05-09 2024-08-16 昆明医科大学 一种靶向降解β-catenin的多肽型抑制剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) * 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US5800347A (en) * 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) * 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
EP1179092A2 (en) * 1999-01-10 2002-02-13 Exact Sciences Corporation Methods of detecting colorectal disease by conduction an assay to detect a mutation in a bat-26 locus
US20010041365A1 (en) * 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20050153382A1 (en) * 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
EP2336779B1 (en) * 2004-02-19 2013-07-31 Yale University Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
CN101014859A (zh) * 2004-08-13 2007-08-08 因迪维姆德有限公司 运甲状腺素蛋白作为结肠直肠腺瘤和/或癌的生物标志的用途；检测方法和测试系统
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
EP2177910A1 (en) * 2005-11-10 2010-04-21 Aurelium Biopharma Inc. Tissue diagnostics for breast cancer
ES2565512T3 (es) * 2007-07-19 2016-04-05 bioMérieux Procedimiento de ensayo de la proteína de unión a ácidos grasos del hígado, de ACE y de CA19-9 para el diagnóstico in vitro del cáncer colorrectal
EP2195658A2 (en) * 2007-09-28 2010-06-16 Royal College of Surgeons in Ireland A method of assessing colorectal cancer status in an individual
CA2701970A1 (en) * 2007-12-10 2009-06-18 F. Hoffmann-La Roche Ag Marker panel for colorectal cancer
CA2706115A1 (en) * 2007-12-10 2009-06-18 F. Hoffmann-La Roche Ag Seprase as a marker for cancer
AU2009213671A1 (en) * 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (CCAT1) as a cancer marker
US20110076700A1 (en) * 2008-02-29 2011-03-31 Nihon University Anti-crp antibody and utilization of the same
EP2255017A1 (en) * 2008-03-18 2010-12-01 Epigenomics AG A method for optimizing and validating an assay for determining the presence or absence of a medical condition
CA2724433A1 (en) * 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
EP2796878A1 (en) * 2008-05-23 2014-10-29 Biocartis NV New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
AU2010306593B2 (en) * 2009-10-15 2015-09-10 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring inflammatory disease activity
US10119959B2 (en) * 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
EP2668503B1 (en) * 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in lung cancer patient management
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2845568A1 (en) * 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection

Also Published As

Publication number Publication date
CN104969071A (zh) 2015-10-07
US20150111220A1 (en) 2015-04-23
CA2893158A1 (en) 2014-06-05
US20150111223A1 (en) 2015-04-23
KR20150090240A (ko) 2015-08-05
WO2014085826A2 (en) 2014-06-05
EP2926138A4 (en) 2016-09-14
JP2016507723A (ja) 2016-03-10
CN104969071B (zh) 2019-09-03
US20140234854A1 (en) 2014-08-21
BR112015012616A2 (pt) 2017-09-12
US20150111221A1 (en) 2015-04-23
EP2926138A2 (en) 2015-10-07
CN110596385A (zh) 2019-12-20
US20150111230A1 (en) 2015-04-23
SG11201504241QA (en) 2015-06-29
AU2013351947A1 (en) 2015-06-18
WO2014085826A3 (en) 2014-10-23
US20170285033A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
MX2015006757A (es) Método para la evaluación de la presencia de o riesgo de tumores de colon.
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
HK1255533A1 (zh) 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板
WO2015109263A3 (en) Biomarkers for detecting and monitoring colon cancer
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
WO2013028680A3 (en) Method and apparatus for detecting a biomarker in the presence of electrical stimulation
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
MX2015015532A (es) Metodo y sistema de identificacion de biomarcadores.
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
GB201021399D0 (en) Oligonucleotide probe set and methods of microbiota profiling
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
GB2483810B (en) Methods for correlating clonotypes with diseases in a population
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
BR112013006683A2 (pt) diagnóstico de câncer de mama
BR112013023050A2 (pt) “antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal”
MX362041B (es) Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2009155096A3 (en) Assessing tumor response to therapy
IN2014DN08398A (cg-RX-API-DMAC7.html)
MX2016003772A (es) Aparatos y metodos de analisis de datos.
EA201490946A1 (ru) Способ количественной оценки лечения рака